An Illumina press-release:
ILLUMINA LAUNCHES THE HUMAN CNV370-DUO DNA ANALYSIS BEADCHIP FOR COPY NUMBER VARIATION RESEARCH

SAN DIEGO, March 12, 2007 -- Illumina, Inc. (NASDAQ: ILMN) today announced the launch of a new DNA Analysis BeadChip developed in collaboration with deCODE genetics. The new product, called the HumanCNV370-Duo, is the world’s first microarray designed to specifically target novel regions of the genome that show copy number variation (CNV). Copy number variations can occur when a region within a chromosome or an entire chromosome is randomly amplified or deleted. DNA copy number of certain genomic regions can vary widely from person to person and has already been linked to cancers, congenital disorders, and other common diseases. Priced attractively, the HumanCNV370-Duo will allow researchers to increase the number of samples analyzed, while maintaining unprecedented data quality.

Powered by Illumina’s Infinium® Assay, the HumanCNV370-Duo enables researchers to analyze two samples simultaneously and access novel content for detecting disease-relevant CNV regions. Content found on this BeadChip will also be available on Illumina’s Human 1M, a single-chip solution that will profile over one million diverse genetic variants.

“Before the HumanCNV370-Duo was developed, we did not have a tool that could target select regions of the genome that we believe contain the majority of undiscovered CNVs. Preliminary data from this array demonstrate that we can identify numerous novel CNV regions that were notoriously difficult to define using previous technologies and can look for new disease-associated genes and markers,” said Jeffrey Gulcher, M.D., Ph.D., Chief Scientific Officer of deCODE genetics. “Illumina’s HumanCNV370-Duo will offer researchers superior quality and content as compared to any other CNV products currently available. We look forward to providing our contract genotyping customers the full benefit of this new and exciting product.”
The HumanCNV370-Duo combines the content found on the HumanHap300-Duo with an additional 55,000 markers specifically designed to target approximately 11,000 novel copy number variant regions. In addition to providing broad coverage of SNPs from the International HapMap Project, the HumanCNV370-Duo also provides coverage for regions of the human genome believed to contain the majority of undiscovered CNVs.

“Studying copy number variation adds a new level of information to DNA Analysis, and integrating this information into genotyping studies is essential. Researchers are now looking for a tool that can help them identify CNVs found in unstable genomic regions that are difficult to define by current technologies,” said Daniel Peiffer, Ph.D., Associate Product Manager for DNA Products at Illumina. “By working closely with deCODE and accessing their large set of validated CNV regions not currently available in any public repository, we have been able to specifically select a set of regions that are highly likely to represent functional variants for common and rare diseases.”

“We have had a long-standing relationship with deCODE and worked very closely with them to develop novel content for the HumanCNV370-Duo,” said Jay Flatley, President and Chief Executive Officer of Illumina. “By adding this BeadChip to our growing product portfolio, we have quickly evolved our technologies to meet the needs of the life sciences community through a successful collaboration with a global leader in gene discovery.”

About Copy Number Variation
Research from the past several years show that human copy number variation contributes to a high level of genetic variation. In addition to the information gained from SNP genotyping studies, CNVs will provide additional insights into how large-scale genetic diversity impacts biological function and contributes to both complex and common human diseases.

About Infinium Genotyping and CNV Analysis
Infinium Genotyping utilizes a novel assay together with Illumina's BeadArray(TM) technology to deliver industry-leading performance, genome-wide access and scalable solutions for SNP genotyping and the analysis of CNV. The revolutionary Infinium Assays and corresponding BeadChips allow large-scale interrogation of variation in the human genome, accelerating the ability of researchers to cost-effectively unlock the genetic basis of disease. For more information on Infinium technology and products, visit www.illumina.com/infinium.

About Illumina
Illumina (www.illumina.com) is developing next-generation tools for the large-scale analysis of genetic variation and function.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are the costs and outcome of Illumina's litigation with Affymetrix, our ability to effectively integrate our recent acquisition of Solexa, Inc., Illumina's ability to further develop and commercialize its BeadArray technologies and to deploy new gene expression and genotyping products and applications for its platform technology, Illumina's ability to manufacture robust Sentrix(R) arrays and Oligator(R) oligonucleotides, Illumina's ability to scale and integrate CyVera technology, and other factors detailed in the Company's filings with the Securities and Exchange Commission including its recent filings on Forms 10-K and 10-Q or in information disclosed in public conference calls, the date and time of which are released beforehand. Illumina disclaims any intent or obligation to update these forward-looking statements beyond the date of this release.

SOURCE: Illumina

Illumina, Inc.
Maurissa Bornstein, 858-332-4055
Public Relations Manager
mbornstein@illumina.com

or

deCODE genetics
Pernille Sorensen Baker, Ph.D., 354-570-2807
Director of Marketing, Genotyping Services
genotyping@decode.com